中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
9期
133-135
,共3页
徐世英%曾敬怀%蒋英蓝%秦春宏
徐世英%曾敬懷%蔣英藍%秦春宏
서세영%증경부%장영람%진춘굉
川芎嗪%化疗栓塞%中晚期肝癌%脑源性神经营养因子
川芎嗪%化療栓塞%中晚期肝癌%腦源性神經營養因子
천궁진%화료전새%중만기간암%뇌원성신경영양인자
Keywords ] tetramethylpyrazine%transcatheter hepatic arterial chemoembolization%medium and advanced liver cancer%brain-derived neurotrophic factor
目的：探讨川芎嗪联合化疗治疗中晚期肝癌的疗效及对患者脑源性神经营养因子（ brain-derived neurotrophic factor， BDNF）水平的影响。方法选取2011年1月至2012年6月接受治疗的90例中晚期肝癌患者作为研究对象，按照治疗方案分为对照组42例和观察组48例。对照组给予化疗栓塞（ transcatheter hepatic arterial chemoembolization，TACE）治疗，观察组在对照组基础上联合应用川芎嗪治疗。观察比较2组患者肿瘤近期疗效、长期疗效、BDNF水平及不良反应发生情况。结果治疗后，观察组近期治疗总有效率高于对照组（83.3％vs 64.3％，P＜0.05）。随访3年，对照组1年、2年和3年生存率分别为66.7％、59.5％和30.9％，观察组的分别为75.0％、66.7％和52.1％。2组患者1年、2年生存率比较差异无统计学意义，而观察组3年生存率显著高于对照组（ P＜0.05）。治疗后，观察组BDNF水平显著低于对照组（P＜0.05）。治疗期间，2组患者肝功能恶化、腹痛腹泻、恶心呕吐、发热头痛等不良反应发生率组间比较差异无统计学意义。结论川芎嗪联合化疗栓塞治疗中晚期肝癌疗效可靠，能够一定程度提高肿瘤近期有效率及生存率，明显降低患者BDNF水平，且不增加不良反应发生率，临床上值得进一步研究。
目的：探討川芎嗪聯閤化療治療中晚期肝癌的療效及對患者腦源性神經營養因子（ brain-derived neurotrophic factor， BDNF）水平的影響。方法選取2011年1月至2012年6月接受治療的90例中晚期肝癌患者作為研究對象，按照治療方案分為對照組42例和觀察組48例。對照組給予化療栓塞（ transcatheter hepatic arterial chemoembolization，TACE）治療，觀察組在對照組基礎上聯閤應用川芎嗪治療。觀察比較2組患者腫瘤近期療效、長期療效、BDNF水平及不良反應髮生情況。結果治療後，觀察組近期治療總有效率高于對照組（83.3％vs 64.3％，P＜0.05）。隨訪3年，對照組1年、2年和3年生存率分彆為66.7％、59.5％和30.9％，觀察組的分彆為75.0％、66.7％和52.1％。2組患者1年、2年生存率比較差異無統計學意義，而觀察組3年生存率顯著高于對照組（ P＜0.05）。治療後，觀察組BDNF水平顯著低于對照組（P＜0.05）。治療期間，2組患者肝功能噁化、腹痛腹瀉、噁心嘔吐、髮熱頭痛等不良反應髮生率組間比較差異無統計學意義。結論川芎嗪聯閤化療栓塞治療中晚期肝癌療效可靠，能夠一定程度提高腫瘤近期有效率及生存率，明顯降低患者BDNF水平，且不增加不良反應髮生率，臨床上值得進一步研究。
목적：탐토천궁진연합화료치료중만기간암적료효급대환자뇌원성신경영양인자（ brain-derived neurotrophic factor， BDNF）수평적영향。방법선취2011년1월지2012년6월접수치료적90례중만기간암환자작위연구대상，안조치료방안분위대조조42례화관찰조48례。대조조급여화료전새（ transcatheter hepatic arterial chemoembolization，TACE）치료，관찰조재대조조기출상연합응용천궁진치료。관찰비교2조환자종류근기료효、장기료효、BDNF수평급불량반응발생정황。결과치료후，관찰조근기치료총유효솔고우대조조（83.3％vs 64.3％，P＜0.05）。수방3년，대조조1년、2년화3년생존솔분별위66.7％、59.5％화30.9％，관찰조적분별위75.0％、66.7％화52.1％。2조환자1년、2년생존솔비교차이무통계학의의，이관찰조3년생존솔현저고우대조조（ P＜0.05）。치료후，관찰조BDNF수평현저저우대조조（P＜0.05）。치료기간，2조환자간공능악화、복통복사、악심구토、발열두통등불량반응발생솔조간비교차이무통계학의의。결론천궁진연합화료전새치료중만기간암료효가고，능구일정정도제고종류근기유효솔급생존솔，명현강저환자BDNF수평，차불증가불량반응발생솔，림상상치득진일보연구。
Objective To investigate curative efficacy of tetramethylpyrazine in combination with chemotherapy in treatment of medium and advanced liver cancer and its effects on level of brain-derived neurotrophic factor ( BDNF).Methods 90 patients of medium and advanced liver cancer who received therapy from January 2011 to June 2012 were selected as research objects.According to therapeutic schemes, those patients were divided into the control group (n=42) and the observation group (n=48).The control group was treated with transcatheter hepatic arterial chemoembolization ( TACE) , while the observation group was treated with tetramethylpyrazine in combination with TACE.Then, the short-term curative efficacy, long-term curative efficacy, level of BDNF and adverse reactions were compared.Results The total short-term therapeutic efficacy ratio in the observation group was statistically higher than that in the control group ( 83.3% vs 64.3%, P <0.05 ).During the three-year follow-up, the one-year and two-year survival rate in the observation group was statistically same with that in the control group respectively (75.0% vs 66.7%, 66.7% vs 59.5%), while the three-year survival rate was statistically higher than that in the control group (52.1%vs 30.9%, P<0.05).After treatment, in comparison with the control group, level of BDNF in the observation group was statistically lower(P<0.05).During treatment, incidences of liver function deterioration, abdo minal pain and diarrhea, nausea and vomiting, fever and headache in two groups were statistically same.Conclusion Tetramethylpyrazine in combination with TACE is effective for medium and advanced liver cancer, which can increase short-term and survival rate to some extent, significantly reduce level of BDNF with not increasing incidence of adverse reactions.
